NewMarketOverview: Global Cardiovascular Drugs Market


Published on

Global Cardiovascular Drugs market to decline at a CAGR of 10.47 percent over the period 2012-2016. One of the key factors affecting market growth is the over-dependency of the market on the US. The Global Cardiovascular Drugs market has also been witnessing an increase in R&D activities.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

NewMarketOverview: Global Cardiovascular Drugs Market

  1. 1. Global Cardiovascular Drugs Market 2012-2016TechNavios analysts forecast the Global Cardiovascular Drugs market to decline at a CAGR of 10.47 percentover the period 2012-2016. One of the key factors affecting market growth is the over-dependency of themarket on the US. The Global Cardiovascular Drugs market has also been witnessing an increase in R&Dactivities. However, the increase in healthcare expenditure could be one of the factors that will contribute tothe growth of this market.TechNavios report, the Global Cardiovascular Drugs Market 2012-2016, has been prepared based on anin-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEAand APAC regions; it covers the Global Cardiovascular Drugs market landscape and its growth prospects inthe coming years. The report also includes a discussion of the key vendors operating in this market.The key vendors dominating this market space are AstraZeneca plc, Bristol-Myers Squibb Co., Merck & Co.Inc., Novartis AG, Pfizer Inc., and Sanofi.The other vendors mentioned in the report are Abbott Laboratories, Forest Laboratories Inc., F. Hoffmann-LaRoche Ltd., Bayer AG, Daiichi Sankyo Co. Ltd., GlaxoSmithKline plc, Solvay SA, Takeda PharmaceuticalCo. Ltd., and The Medicines Co.Key questions answered in this report:What will the market size be in 2016 and at what rate will it grow?What are the key market trends?What is driving this market?What are the challenges to market growth?Who are the key vendors in this market space?What are the market opportunities and threats faced by these key vendors?What are the strengths and weaknesses of these key vendors?1. Executive Summary2. Introduction3. Market Coveragemarket Overviewproduct Offerings4. Market Landscape4.1. Global Cardiovascular Drugs Marketmarket Size And Forecast4.2. Key Product Segmentation4.3. Five Force AnalysisGlobal Cardiovascular Drugs Market 2012-2016
  2. 2. 5. Global Anti-hypertensive Drugs Marketmarket Overviewmarket Size And Forecast6. Best Selling Anti-hypertensive Drugs6.1. Diovan/co-diovanmarket Overviewmarket Size And Forecast6.2. Blopressmarket Overviewmarket Size And Forecast6.3. Benicar/benicar Hctmarket Overviewmarket Size And Forecast6.4. Micardis/micardis Hctmarket Overviewmarket Size And Forecast6.5. Aprovel/coaprovel (avapro/avalide)market Overviewmarket Size And Forecast6.6. Tekturna/rasilezmarket Overviewmarket Size And Forecast6.7. Edarbimarket Overview6.8. Cozaar/hyzaarmarket Overviewmarket Size And Forecast6.9. Norvascmarket Overviewmarket Size And Forecast6.10. Exforge/exforge Hctmarket Overviewmarket Size And Forecast6.11. Coversylmarket Overviewmarket Size And Forecast6.12. Seloken/toprol-xlmarket Overviewmarket Size And Forecast7. Global Anti-dyslipidemics Drugs Marketmarket Overviewmarket Size And Forecast8. Best Selling Anti-dyslipidemic DrugsGlobal Cardiovascular Drugs Market 2012-2016
  3. 3. 8.1. Lipitormarket Overviewmarket Size And Forecast8.2. Crestormarket Overviewmarket Size And Forecast8.3. Niaspanmarket Overviewmarket Size And Forecast8.4. Tricor/trilipixmarket Overviewmarket Size And Forecast8.5. Zetia/vytorinmarket Overviewmarket Size And Forecast8.6. Tredaptivemarket Overview9. Global Anti-thrombotics Drugs Marketmarket Overviewmarket Size And Forecast10. Best Selling Anti-thrombotic Drugs10.1. Plavixmarket Overviewmarket Size And Forecast10.2. Lovenoxmarket Overviewmarket Size And Forecast10.3. Pradaxamarket Overviewmarket Size And Forecast10.4. Xareltomarket Overview10.5. Brilique/brilintamarket Overview10.6. Eliquismarket Overview11. Drug Pipeline Analysis12. Geographical Segmentation13. Key Leading Countriesusagermanyjapan14. Rate Of Incidence And PrevalenceGlobal Cardiovascular Drugs Market 2012-2016
  4. 4. dyslipidemiahypertensionhypercholesterolemiastroke15. Vendor Landscape16. Buying Criteria17. Market Challenges18. Market Growth Drivers19. Drivers And Their Impact20. Impact Of Drivers And Challenges21. Market Trends22. Key Vendor Analysis22.1. Pfizer Inc.22.1.1. Business Overview22.1.2. Business Segmentation22.1.3. Key Information22.1.4. Swot Analysis22.2. Bristol-myers Squibb Co.22.2.1. Business Overview22.2.2. Business Segmentation22.2.3. Key Information22.2.4. Swot Analysis22.3. Astrazeneca Plc22.3.1. Business Overview22.3.2. Business Segmentation22.3.3. Key Information22.3.4. Swot Analysis22.4. Novartis Ag22.4.1. Business Overview22.4.2. Business Segmentation22.4.3. Key Information22.4.4. Swot Analysis22.5. Merck & Co. Inc.22.5.1. Business Overview22.5.2. Business Segmentation22.5.3. Key Information22.5.4. Swot Analysis22.6. Sanofi S.a.22.6.1. Business Overview22.6.2. Business Segmentation22.6.3. Key Information22.6.4. Swot Analysis23. Other Reports In This SeriesGlobal Cardiovascular Drugs Market 2012-2016
  5. 5. list Of Exhibits:exhibit 1: Global Cardiovascular Drugs Market 2012-2016 (us$ Billion)exhibit 2: Cardiovascular Drugs By Category Segmentationexhibit 3: Global Cardiovascular Drugs Market By Category Segmentation 2012 (percent)exhibit 4: Global Cardiovascular Drugs Market By Category Segmentation 2012-2016 (us$ Million)exhibit 5: Global Cardiovascular Drugs Market By Category Segmentation 2012-2016 (in Percent)exhibit 6: Global Anti-hypertensive Market 2012-2016 (us$ Million)exhibit 7: Global Sales Of Diovan/co-diovan 2012-2016 (us$ Billion )exhibit 8: Global Sales Of Blopress/ecard (atacand/atacand Plus) 2012-2016 (us$ Billion)exhibit 9: Global Sales Of Benicar/benicar Hct 2012-2016 (us$ Billion)exhibit 10: Global Sales Of Micardis/micardis Hct 2012-2016 (us$ Billion)exhibit 11: Global Sales Of Aprovel/coaprovel (avapro/avalide) 2012-2016 (us$ Billion)exhibit 12: Global Sales Of Tekturna/rasilez 2012-2016 (us$ Million)exhibit 13: Global Sales Of Cozaar/hyzaar 2012-2016 (us$ Million)exhibit 14: Global Sales Of Norvasc 2012-2016 (us$ Billion)exhibit 15: Global Sales Of Exforge/exforge Hct 2012-2016 (us$ Billion)exhibit 16: Global Sales Of Coversyl 2012-2016 (us$ Million)exhibit 17: Global Sales Of Seloken/toprol-xl 2012-2016 (us$ Million)exhibit 18: Global Anti-dyslipidemic Market 2012-2016 (us$ Million)exhibit 19: Global Sales Of Lipitor 2012-2016 (us$ Billion)exhibit 20: Global Sales Of Crestor 2012-2016 (us$ Billion)exhibit 21: Global Sales Of Niaspan 2012-2016 (us$ Million)exhibit 22: Global Sales Of Tricor/trilipix 2012-2016 (us$ Million)exhibit 23: Global Sales Of Zetia 2012-2016 (us$ Billion)exhibit 24: Global Sales Of Vytorin 2012-2016 (us$ Billion)exhibit 25: Global Anti-thrombotic Market 2012-2016 (us$ Million)exhibit 26: Global Sales Of Plavix 2012-2016(us$ Billion)exhibit 27: Global Sales Of Lovenox 2012-2016 (us$ Billion)exhibit 28: Global Sales Of Pradaxa 2012-2016 (us$ Million)exhibit 29: Oral Hdl-c-raising Pipeline Drugsexhibit 30: Parenteral Hdl-c-raising Pipeline Drugsexhibit 31: Severe Hypercholesterolemia Pipeline Drugsexhibit 32: Anti-inflammatory Pipeline Drugsexhibit 33: Heart Failure Pipeline Drugsexhibit 34: Global Cardiovascular Drugs Market By Geographical Segmentation 2012exhibit 35: Prevalence Of Hypertension In 2012exhibit 36: Prevalence Of Hypercholesterolemia In 2012exhibit 37: Prevalence Of Stroke In 2012exhibit 38: Global Cardiovascular Drugs Market By Vendor Segmentation 2012exhibit 39: Global Cardiovascular Drugs Market By Vendor Segmentation 2016exhibit 40: Business Segmentation Of Pfizer Inc.exhibit 41: Business Segmentation Of Bristol-myers Squibb Co.exhibit 42: Business Segmentation Of Astrazeneca PlcGlobal Cardiovascular Drugs Market 2012-2016
  6. 6. exhibit 43: Business Segmentation Of Novartis Agexhibit 44: Business Segmentation Of Merck & Co. Inc.exhibit 45: Business Segmentation Of Sanofi S.a.About Us:Transparency Market Research is a market intelligence company providing global business informationreports and services. Our exclusive blend of quantitative forecasting and trends analysis providesforward-looking insight for thousands of decision makers. We are privileged with highly experienced team ofAnalysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques togather, and analyze information. Our business offerings represent the latest and the most reliable informationindispensable for businesses to sustain a competitive edge.Contact:ResearchMoz90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usBlog: Cardiovascular Drugs Market 2012-2016